Health Care

Harbin Pharmaceutical Group’s 5‑day limit‑up streak showcases its innovation‑drug strength amid market weakness, highlighting strong fundamentals and growing investor confidence.

Learn how Eli Lilly’s $3.8 billion purchase of AtaiBeckley marks a bold move into psychedelic medicine, boosting its portfolio and future growth.

Compass Pathways’ post‑hoc analysis shows minimal support can drive psilocybin’s PTSD benefits, challenging costly psychotherapy models and opening scalable, insurer‑friendly paths for psychedelic treatment.

Satellos Bioscience: pioneering muscle‑regeneration therapies in Canada, boosting healing for severe muscle disorders with cutting‑edge biotech innovations.

Discover how Carl Zeiss Meditec AG dominates ophthalmology tech, drives global eye‑care innovation, and delivers strong investor returns.

European Commission approves Wegovy tablet; Novo Nordisk sees strong investor lift and positive long‑term data on hemophilia candidate Denecimig.

Pharmaron boosts its CDMO outlook, driving 10% profit growth and a 6.8% margin, as demand for contract drug development surges in a rebounding healthcare market.

Explore Hefei Lifeon Pharmaceutical’s solid mid‑cap profile, diversified drug lineup, and growing investor interest amid China’s healthcare reforms.

Orexo AB’s Q2 2026 results show a deepening loss but a hopeful clinical roadmap—key FDA milestones could turn debt‑heavy biotech into a growth story.

Explore how Lumos Diagnostics’ performance-rights securities were discontinued—yet the company’s point‑of‑care diagnostics and ASX trading remain robust.